A200670 Stock Overview
Engages in the manufacture and sale of various pharmaceutical products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 1/6 |
Humedix Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩30,200.00 |
| 52 Week High | ₩39,900.00 |
| 52 Week Low | ₩25,400.00 |
| Beta | 0 |
| 11 Month Change | -1.79% |
| 3 Month Change | -13.59% |
| 1 Year Change | -12.72% |
| 33 Year Change | 23.52% |
| 5 Year Change | 26.36% |
| Change since IPO | 5.94% |
Recent News & Updates
Recent updates
Humedix (KOSDAQ:200670) Has A Pretty Healthy Balance Sheet
Mar 09
Humedix Co., Ltd.'s (KOSDAQ:200670) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Feb 16Should You Buy Humedix Co., Ltd. (KOSDAQ:200670) For Its Dividend?
Jan 28Are Humedix's (KOSDAQ:200670) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 11
What Type Of Returns Would Humedix's(KOSDAQ:200670) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Dec 22Here's Why Humedix (KOSDAQ:200670) Can Manage Its Debt Responsibly
Dec 01Shareholder Returns
| A200670 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 18.2% | -3.0% | 2.3% |
| 1Y | -12.7% | 6.3% | -3.8% |
Return vs Industry: A200670 underperformed the KR Pharmaceuticals industry which returned 6.3% over the past year.
Return vs Market: A200670 underperformed the KR Market which returned -3.8% over the past year.
Price Volatility
| A200670 volatility | |
|---|---|
| A200670 Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.4% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A200670 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A200670's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Jin-hwan Kim | humedix.com |
Humedix Co., Ltd. engages in the manufacture and sale of various pharmaceutical products in South Korea. The company offers prescription medicines, active pharmaceutical ingredients, medical devices, cosmetic, and health functional food products. It is also involved in manufacture and distribution of anticancer drugs.
Humedix Co., Ltd. Fundamentals Summary
| A200670 fundamental statistics | |
|---|---|
| Market cap | ₩313.93b |
| Earnings (TTM) | ₩9.06b |
| Revenue (TTM) | ₩110.99b |
0.0x
P/E Ratio0.0x
P/S RatioIs A200670 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A200670 income statement (TTM) | |
|---|---|
| Revenue | ₩110.99b |
| Cost of Revenue | ₩66.92b |
| Gross Profit | ₩44.07b |
| Other Expenses | ₩35.00b |
| Earnings | ₩9.06b |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A200670 perform over the long term?
See historical performance and comparison